Dengue virus serotypes 1–4 (DENV)

Dengue virus (DENV) is a single-stranded, positive-sense RNA virus of the Flaviviridae family, existing as four distinct but closely related serotypes (DENV-1, DENV-2, DENV-3, and DENV-4). It is the causative agent of dengue fever, a major mosquito-borne disease transmitted primarily by Aedes aegypti. The viral genome encodes a polyprotein that is processed into structural proteins (C, prM, E) and non-structural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, NS5), which are essential for the viral life cycle. These proteins, particularly the NS5 polymerase and NS3 protease, are the primary targets for direct-acting antivirals, while the Envelope (E) protein is the focus of vaccine development. A critical challenge in targeting DENV is antibody-dependent enhancement (ADE), where non-neutralizing antibodies from a previous infection or vaccination can facilitate the entry of a different serotype into host cells, increasing the risk of severe disease. Consequently, therapeutic and prophylactic efforts must achieve balanced, tetravalent protection across all four serotypes to ensure safety and efficacy.

Other names

Dengue virusDENV-1DENV-2DENV-3DENV-4Dengue fever virus

Vaccines induce neutralizing antibodies against the Envelope (E) protein of all four serotypes. Antiviral candidates target specific viral proteins such as the NS5 RNA-dependent RNA polymerase to inhibit replication, the NS2B-NS3 protease to prevent polyprotein processing, or the NS4B protein to block viral replication complex formation.